HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Antibacterial claims

This article was originally published in The Rose Sheet

Executive Summary

FTC finalizes consent agreement with Unilever Home & Personal Care on charges the company lacks adequate substantiation to support ad claims for Vaseline Intensive Care Anti-Bacterial Hand Lotion. The ads claimed the product "stops germs longer than washing alone" and provides enough germ protection to "stop germs for hours." The settlement bars Unilever from making claims about any antimicrobial product unless it possesses scientific substantiation. The consent agreement was reached in September (1"The Rose Sheet" Sept. 20, 1999, p. 7)

You may also be interested in...



Unilever Vaseline Lotion Germ Protection Claims Deceptive - FTC Order

Advertisements for Unilever's Vaseline Brand Intensive Care Antibacterial Hand Lotion carry unsubstantiated, deceptive claims for the product's germ protecting properties, the Federal Trade Commission states in a Sept. 15 proposed consent agreement with the company.

OCA Applauds Organic Board's Recommendation To USDA: "Outlaw Nanotech"

With a push from the Organic Consumers Association, the National Organic Standards Board is recommending that the use of nanotechnology be strictly prohibited from products certified under the National Organic Program

Beauty Claims Inch Closer To Pharma As Cosmeceutical Sector Expands

Though global market-size estimates differ, analysts at SupplySide West 2010 in Las Vegas agreed that cosmeceuticals remain a promising growth vehicle

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007529

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel